Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.50)
# 291
Out of 5,148 analysts
144
Total ratings
55.97%
Success rate
19.92%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $8 → $10 | $4.97 | +101.21% | 8 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $135 → $140 | $101.29 | +38.22% | 2 | Feb 27, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $150 → $100 | $13.42 | +645.16% | 8 | Feb 27, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $90.09 | +44.30% | 7 | Dec 8, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $7.78 | +221.34% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $132.61 | +50.82% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $3.30 | +809.09% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $65.50 | +67.94% | 13 | Oct 30, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.72 | +481.40% | 1 | Oct 6, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $57.76 | +29.85% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.00 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $28.64 | -12.71% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $12.57 | +98.89% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $7.02 | -14.53% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $242.09 | +15.66% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $5.47 | +814.08% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $5.77 | +246.62% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $258.81 | -16.93% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.19 | +128.31% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.76 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $9.17 | +227.15% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.33 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.21 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $40.68 | +121.24% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.35 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $146.32 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $64.33 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.35 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.52 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $114.05 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $10.97 | +993.89% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $42.55 | +52.76% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $13.98 | -64.23% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $14.53 | -24.29% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $132.38 | -1.80% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $790.81 | -3.90% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $23.31 | -35.65% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $15.99 | +243.96% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.37 | +2,089.78% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.16 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.24 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $435.62 | -42.61% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $100.04 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $81.96 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.15 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $10.50 | +109.52% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.95 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $59.74 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $234.26 | -59.45% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $4.97
Upside: +101.21%
Nuvalent
Feb 27, 2026
Maintains: Overweight
Price Target: $135 → $140
Current: $101.29
Upside: +38.22%
Janux Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $150 → $100
Current: $13.42
Upside: +645.16%
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $90.09
Upside: +44.30%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $7.78
Upside: +221.34%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $132.61
Upside: +50.82%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $3.30
Upside: +809.09%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $65.50
Upside: +67.94%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.72
Upside: +481.40%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $57.76
Upside: +29.85%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $21.00
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $28.64
Upside: -12.71%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $12.57
Upside: +98.89%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $7.02
Upside: -14.53%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $242.09
Upside: +15.66%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $5.47
Upside: +814.08%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $5.77
Upside: +246.62%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $258.81
Upside: -16.93%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.19
Upside: +128.31%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.76
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $9.17
Upside: +227.15%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.33
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.21
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $40.68
Upside: +121.24%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.35
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $146.32
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.33
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.35
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $114.05
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $10.97
Upside: +993.89%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $42.55
Upside: +52.76%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $13.98
Upside: -64.23%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $14.53
Upside: -24.29%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $132.38
Upside: -1.80%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $790.81
Upside: -3.90%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $23.31
Upside: -35.65%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $15.99
Upside: +243.96%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.37
Upside: +2,089.78%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.16
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $9.24
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $435.62
Upside: -42.61%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $100.04
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $81.96
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.15
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $10.50
Upside: +109.52%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $18.95
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $59.74
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $234.26
Upside: -59.45%